Novartis Aktie

99,88 EUR -0,62 EUR -0,62 %

30.04.2025

L&S

93,79 CHF -0,42 CHF -0,45 %

30.04.2025

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.190,30 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

27.11.24Dow JonesPress Release: Novartis Kisqali(R) receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of...

25.11.24GlobeNewswireNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

25.11.24Dow JonesPress Release: Novartis highlights new 96-week -2-

25.11.24Dow JonesPress Release: Novartis highlights new 96-week results from Phase III Scemblix(R) ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali(R)...

22.11.24ZacksNovartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

21.11.24BenzingaNovartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

21.11.24GlobeNewswireNovartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

21.11.24Dow JonesPress Release: Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

19.11.24GlobeNewswireNovartis ranks first in 2024 Access to Medicine Index

18.11.24ZacksAlcon (ALC) is a Top-Ranked Value Stock: Should You Buy?

18.11.24PR NewswireRatio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

15.11.24ZacksHere's Why Novartis (NVS) is a Strong Value Stock

14.11.24ZacksDown -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

14.11.24ZacksZacks.com featured highlights include Janus Henderson, Coastal Financial, Novartis, Apogee and InterDigital

13.11.24ZacksAlcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

13.11.24ZacksNovartis (NVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

13.11.24ZacksDown -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

12.11.24ZacksAlcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

12.11.24BenzingaSchrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

12.11.24MarketWatchSchrödinger’s stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion

07.11.24ZacksWhat Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings

05.11.24ZacksIs Novartis (NVS) Stock Undervalued Right Now?

30.10.24BenzingaPositive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

30.10.24ZacksWhy Novartis (NVS) is a Top Value Stock for the Long-Term

29.10.24GlobeNewswireNovartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

29.10.24MotleyFoolNovartis Ag (NVS) Q3 2024 Earnings Call Transcript

29.10.24ZacksNovartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook

29.10.24ZacksNovartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

29.10.24BenzingaNovartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook

29.10.24ZacksThe Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies

29.10.24GlobeNewswireNovartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance

29.10.24Dow JonesPress Release: Novartis continues strong momentum -3-

29.10.24Dow JonesPress Release: Novartis continues strong momentum -2-

29.10.24Dow JonesPress Release: Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises ...

27.10.24GlobeNewswireNovartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

27.10.24Dow JonesPress Release: Novartis oral Fabhalta(R) -2-

27.10.24Dow JonesPress Release: Novartis oral Fabhalta(R) (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

24.10.24ZacksStay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

24.10.24ZacksThe Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

24.10.24GlobeNewswireNovartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.